Teva Pharmaceutical Indus TEVA has outperformed the market over the past 5 years by 2.65% on an annualized basis producing an average annual return of 15.91%. Currently, Teva Pharmaceutical Indus ...

The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...

TEVA) were slipping Wednesday. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) lost 0.5% and 0.9%, respectively. Teva reported earnings before trading ...

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone.

which Sanofi licensed from Teva in a deal valued at around $1.5 billion last year. TL1A – or tumour necrosis factor-like ligand 1A – has become something of a hot topic in IBD, with other ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...